crenigacestat
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT03502577 | May 2018 → Apr 2022 | plasma cell myeloma | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT02784795 | Nov 2016 → Aug 2018 | breast cancer, cholangiocarcinoma, colon carcinoma, soft tissue sarcoma | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT02906618 | Oct → Nov 2016 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02836600 | Sep 2016 → Jul 2019 | neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02917733 | Sep → Nov 2016 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02659865 | Jan → Jun 2016 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01695005 | Oct 2012 → Jun 2018 | lymphoma, metastatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02518113 | Oct 2015 → Jan 2018 | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | crenigacestat | “We aimed to evaluate the safety and identify the recommended phase 2 dose of BCMA CAR T cells in combination with crenigacestat (LY3039478) for individuals with relapsed or...” PMID 37414012 ↗ Jul 20234“Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.” PMID 33107983 ↗ Oct 2020 “Crenigacestat (LY3039478) prevents cleavage of Notch proteins and may benefit patients with relapsed or refractory NHL or CLL.” PMID 40756609 ↗ Jul 2025 “Crenigacestat (LY3039478), a potent Notch inhibitor, decreases Notch signaling and its downstream biologic effects.” PMID 33686452 ↗ Mar 2021 “A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors.” PMID 32939607 ↗ Sep 2020 |
| Known as | JSMD-194 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2338397 ↗ |
| Known as | LY3039478 | “Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.” PMID 33107983 ↗ Oct 20208“A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors.” PMID 32939607 ↗ Sep 2020 “LY3039478” NCT03502577 ↗ |
| Action | Inhibit | “Crenigacestat (LY3039478) prevents cleavage of Notch proteins and may benefit patients with relapsed or refractory NHL or CLL.” PMID 40756609 ↗ Jul 2025 |
| Modality | Small molecule | — CHEMBL2338397 ↗ |
| Route | Oral | “Administered orally” NCT01695005 ↗ |